HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Karo Grabs Sweden’s Trimb To Grow Presence In Nordics

Executive Summary

Karo’s new private-equity owners have flexed their muscles to snap up Sweden’s Trimb in a move which will expand the company’s reach in the Nordics and beyond.

You may also be interested in...



BioGaia Gets Private Equity Backing To Fuel Growth

Probiotics specialist BioGaia will draw on the experience of its new private equity investor EQT as it looks to expand through acquisitions and increased digitization.

European OTC Results Round-Up: Boiron, Alliance Pharma and Karo

COVID-19 had a differing impact on Q2 consumer health sales for France's Boiron, the UK's Alliance Pharma and Sweden's Karo.

Sweden's Karo Snaps Up LEO's OTC Derma Brands

Karo Pharma will pay LEO Pharma €90m for a basket of dermatology and anti-hemorrhoid brands to expand its European footprint.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS148940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel